Wall Street brokerages expect Esperion Therapeutics, Inc. (NASDAQ:ESPR) to announce earnings per share (EPS) of ($2.08) for the current quarter, Zacks reports. Four analysts have made estimates for Esperion Therapeutics’ earnings, with estimates ranging from ($3.32) to ($0.07). Esperion Therapeutics posted earnings per share of ($2.84) during the same quarter last year, which suggests a positive year over year growth rate of 26.8%. The company is scheduled to issue its next earnings results after the market closes on Tuesday, May 4th.
According to Zacks, analysts expect that Esperion Therapeutics will report full year earnings of ($9.48) per share for the current year, with EPS estimates ranging from ($11.25) to ($7.88). For the next year, analysts forecast that the firm will post earnings of ($5.14) per share, with EPS estimates ranging from ($9.00) to $1.28. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Esperion Therapeutics.
Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Monday, February 22nd. The biopharmaceutical company reported ($3.89) EPS for the quarter, missing the consensus estimate of ($3.76) by ($0.13). The company had revenue of $9.64 million for the quarter, compared to analyst estimates of $12.52 million. Esperion Therapeutics had a negative return on equity of 629.88% and a negative net margin of 46.15%. The business’s quarterly revenue was up 881.5% on a year-over-year basis. During the same quarter last year, the business posted ($2.26) earnings per share.
A number of institutional investors have recently made changes to their positions in ESPR. Marshall Wace LLP acquired a new stake in Esperion Therapeutics during the 1st quarter valued at $186,000. Cubist Systematic Strategies LLC lifted its holdings in Esperion Therapeutics by 773.3% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 20,960 shares of the biopharmaceutical company’s stock valued at $779,000 after purchasing an additional 18,560 shares during the last quarter. Brinker Capital Investments LLC acquired a new stake in Esperion Therapeutics during the 3rd quarter valued at $220,000. Rhenman & Partners Asset Management AB lifted its holdings in Esperion Therapeutics by 30.2% during the 4th quarter. Rhenman & Partners Asset Management AB now owns 592,225 shares of the biopharmaceutical company’s stock valued at $15,398,000 after purchasing an additional 137,225 shares during the last quarter. Finally, Pacer Advisors Inc. lifted its holdings in Esperion Therapeutics by 75.3% during the 4th quarter. Pacer Advisors Inc. now owns 4,236 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 1,820 shares during the last quarter.
Shares of ESPR traded down $1.11 during mid-day trading on Tuesday, hitting $25.59. 796,249 shares of the company’s stock were exchanged, compared to its average volume of 719,737. The company has a market cap of $720.51 million, a PE ratio of -6.40 and a beta of 1.48. Esperion Therapeutics has a 52 week low of $23.90 and a 52 week high of $53.73. The company has a 50-day simple moving average of $27.92 and a 200 day simple moving average of $28.95.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States and internationally. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.
Read More: Why Invest in Dividend Kings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.